167 related articles for article (PubMed ID: 12705852)
1. Asparagine endopeptidase can initiate the removal of the MHC class II invariant chain chaperone.
Manoury B; Mazzeo D; Li DN; Billson J; Loak K; Benaroch P; Watts C
Immunity; 2003 Apr; 18(4):489-98. PubMed ID: 12705852
[TBL] [Abstract][Full Text] [Related]
2. Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice.
Maehr R; Hang HC; Mintern JD; Kim YM; Cuvillier A; Nishimura M; Yamada K; Shirahama-Noda K; Hara-Nishimura I; Ploegh HL
J Immunol; 2005 Jun; 174(11):7066-74. PubMed ID: 15905550
[TBL] [Abstract][Full Text] [Related]
3. Lysosomal cysteine and aspartic proteases are heterogeneously expressed and act redundantly to initiate human invariant chain degradation.
Costantino CM; Hang HC; Kent SC; Hafler DA; Ploegh HL
J Immunol; 2008 Mar; 180(5):2876-85. PubMed ID: 18292509
[TBL] [Abstract][Full Text] [Related]
4. Invariant chain processing is independent of cathepsin variation between primary human B cells/dendritic cells and B-lymphoblastoid cells.
Reich M; Zou F; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
Cell Immunol; 2011; 269(2):96-103. PubMed ID: 21543057
[TBL] [Abstract][Full Text] [Related]
5. Lysosomal cysteine proteases and antigen presentation.
Rudensky A; Beers C
Ernst Schering Res Found Workshop; 2006; (56):81-95. PubMed ID: 16329647
[TBL] [Abstract][Full Text] [Related]
6. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
[TBL] [Abstract][Full Text] [Related]
7. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.
Bangia N; Watts TH
Int Immunol; 1995 Oct; 7(10):1585-91. PubMed ID: 8562503
[TBL] [Abstract][Full Text] [Related]
8. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages.
Shi GP; Bryant RA; Riese R; Verhelst S; Driessen C; Li Z; Bromme D; Ploegh HL; Chapman HA
J Exp Med; 2000 Apr; 191(7):1177-86. PubMed ID: 10748235
[TBL] [Abstract][Full Text] [Related]
9. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
[TBL] [Abstract][Full Text] [Related]
10. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo.
Beers C; Burich A; Kleijmeer MJ; Griffith JM; Wong P; Rudensky AY
J Immunol; 2005 Feb; 174(3):1205-12. PubMed ID: 15661874
[TBL] [Abstract][Full Text] [Related]
12. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
13. The proteolytic environment involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain.
Fineschi B; Sakaguchi K; Appella E; Miller J
J Immunol; 1996 Oct; 157(8):3211-5. PubMed ID: 8871612
[TBL] [Abstract][Full Text] [Related]
14. Proteases, processing, and thymic selection.
Cresswell P
Science; 1998 Apr; 280(5362):394-5. PubMed ID: 9575085
[No Abstract] [Full Text] [Related]
15. Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs.
Bania J; Gatti E; Lelouard H; David A; Cappello F; Weber E; Camosseto V; Pierre P
Proc Natl Acad Sci U S A; 2003 May; 100(11):6664-9. PubMed ID: 12748383
[TBL] [Abstract][Full Text] [Related]
16. Effect of decreasing the affinity of the class II-associated invariant chain peptide on the MHC class II peptide repertoire in the presence or absence of H-2M.
Honey K; Forbush K; Jensen PE; Rudensky AY
J Immunol; 2004 Apr; 172(7):4142-50. PubMed ID: 15034026
[TBL] [Abstract][Full Text] [Related]
17. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
[TBL] [Abstract][Full Text] [Related]
18. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
19. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis.
Tolosa E; Li W; Yasuda Y; Wienhold W; Denzin LK; Lautwein A; Driessen C; Schnorrer P; Weber E; Stevanovic S; Kurek R; Melms A; Bromme D
J Clin Invest; 2003 Aug; 112(4):517-26. PubMed ID: 12925692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
